LLY

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Eli Lilly & Co for the quarter ended September 30, 2003. The company operates primarily in the pharmaceutical products segment, with a smaller animal health business. The reporting period includes the three and nine months ended September 30, 2003, compared to the same periods in 2002.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% in Q3 and 12% for the nine-month period, driven by strong performance of Zyprexa, Humalog, Gemzar, and Evista, as well as new product launches (Strattera, Cialis, Forteo).
• Profitability: Q3 net income rose 5% year-over-year, primarily due to an $84.0 million acquired in-process research and development charge in Q3 2002 that did not recur. However, nine-month net income declined 8% due to significant special charges in Q1 2003.
• Special Charges: The nine-month period included $353.9 million in asset impairments, restructuring, and other special charges. These included $186.8 million related to the Isis Pharmaceuticals investment and loan impairment, $114.6 million in manufacturing asset impairments, and $52.5 million in restructuring costs.
• Margins: Gross margins declined to 78.4% in Q3 (from 80.1%) and 78.7% for the nine months (from 80.2%) due to quality improvement costs, capacity expansion, and foreign exchange impacts.
• Operating Expenses: Operating expenses increased 15% in Q3 and 12% for the nine months, driven by higher R&D (clinical trials) and marketing expenses for new launches.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2003 Guidance: Management expects low double-digit sales growth for the full year. Gross margins are expected to contract by approximately 200 basis points due to incremental quality and capacity costs. R&D expenses are expected to increase in the high-single digits, and marketing expenses in the mid-to-high teens.
• Earnings Expectation: The company aligns with analyst consensus of $2.35 EPS for 2003, which includes the Q1 special charges. Q4 2003 EPS is expected to be $0.67 excluding unusual items.
• Liquidity: Cash generated from operations, combined with existing cash balances, is deemed sufficient to fund operations, debt service, capital expenditures, and share repurchases.

Risks and Contingencies

• Patent Litigation: Significant litigation is ongoing regarding generic challenges to Zyprexa (Zenith, Reddy, Teva) and Evista (Barr). An unfavorable outcome could materially impact operations and liquidity. Zyprexa trial is scheduled for January 2004; Evista trial for February 2005.
• Product Liability: The company faces lawsuits regarding Zyprexa (diabetes risk), DES, and thimerosal-containing vaccines. Accruals of approximately $293.8 million have been recorded for environmental and litigation liabilities.
• Regulatory: The FDA has issued warning letters regarding manufacturing practices (cGMP). While progress has been made, final approvals for Cymbalta and Zyprexa IntraMuscular remain contingent on preapproval site inspections and label negotiations.
• Legislative: Potential U.S. legislation (H.R. 2427) regarding drug importation could adversely affect U.S. sales.

Investor Verification Checklist

• Verify the status and potential financial impact of the Zyprexa patent litigation scheduled for trial in January 2004.
• Monitor the resolution of FDA manufacturing compliance issues affecting the launch of Cymbalta and Zyprexa IntraMuscular.
• Assess the sustainability of Zyprexa sales growth in light of FDA warnings regarding diabetes risk and competitive pressures.
• Review the Isis Pharmaceuticals investment impairment details and the status of the Affinitak drug candidate.
• Track the impact of foreign exchange rates on international sales, which contributed significantly to recent growth.